Targets › ASS1
2 programs from 2 companies in 5 trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Gastroenterology, Oncology, Metabolic and endocrine; next expected readout Feb 2027.
One of the enzymes of the urea cycle, the metabolic pathway transforming neurotoxic amonia produced by protein catabolism into inocuous urea in the liver of ureotelic animals. Catalyzes the formation of arginosuccinate from aspartate, citrulline and ATP and together with ASL it is responsible for the biosynthesis of arginine in most body tissues. (UniProt, P00966)
Open in Phaseline: the race on ASS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Polaris Group | ADI-PEG 20 Argininosuccinate synthase 1 (ASS1) depletion via pegylated arginine deiminase | ASS1 | Phase 3 | Hepatocellular Carcinoma; Glioblastoma Multiforme (GBM); Nonalcoholic Steatohepatitis (NASH); Prostate Cancer | Feb 2027 |
| Rebecca Ahrens-Nicklas | LNP.UCD.ABE adenine base editor (ABE) delivered by lipid nanoparticle (LNP) for urea cycle disorder ge | CPS1, OTC, ASS1, ASL, ARG1 | Phase 1 | Urea Cycle Disorders | Sep 2028 |
Hepatocellular Carcinoma (1) Glioblastoma Multiforme (GBM) (1) Nonalcoholic Steatohepatitis (NASH) (1) Prostate Cancer (1) Urea Cycle Disorders (1)
small molecule (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.